123 related articles for article (PubMed ID: 15266174)
21. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma.
Pelikan DM; Lion HL; Hermans J; Goslings BM
Clin Endocrinol (Oxf); 1997 Dec; 47(6):713-20. PubMed ID: 9497879
[TBL] [Abstract][Full Text] [Related]
22. A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer.
Bal C; Chandra P; Kumar A; Dwivedi S
Nucl Med Commun; 2012 Oct; 33(10):1039-47. PubMed ID: 22760303
[TBL] [Abstract][Full Text] [Related]
23. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
24. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
[TBL] [Abstract][Full Text] [Related]
25. Outcome after high-dose radioiodine therapy for advanced differentiated thyroid carcinoma in childhood.
Gao YC; Lu HK
Endocr Res; 2009; 34(4):121-9. PubMed ID: 19878072
[TBL] [Abstract][Full Text] [Related]
26. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
27. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma.
Kita T; Yokoyama K; Higuchi T; Kinuya S; Taki J; Nakajima K; Michigishi T; Tonami N
Ann Nucl Med; 2004 Jun; 18(4):345-9. PubMed ID: 15359929
[TBL] [Abstract][Full Text] [Related]
28. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
29. Survival of differentiated thyroid carcinoma studied in 500 patients.
Lerch H; Schober O; Kuwert T; Saur HB
J Clin Oncol; 1997 May; 15(5):2067-75. PubMed ID: 9164219
[TBL] [Abstract][Full Text] [Related]
30. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma.
Van Tol KM; Hew JM; Jager PL; Vermey A; Dullaart RP; Links TP
Clin Endocrinol (Oxf); 2000 May; 52(5):653-9. PubMed ID: 10792347
[TBL] [Abstract][Full Text] [Related]
31. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
32. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
[TBL] [Abstract][Full Text] [Related]
33. Differentiated thyroid carcinoma in children and young adults: evaluation of response to treatment.
Hod N; Hagag P; Baumer M; Sandbank J; Horne T
Clin Nucl Med; 2005 Jun; 30(6):387-90. PubMed ID: 15891289
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
Durante C; Haddy N; Baudin E; Leboulleux S; Hartl D; Travagli JP; Caillou B; Ricard M; Lumbroso JD; De Vathaire F; Schlumberger M
J Clin Endocrinol Metab; 2006 Aug; 91(8):2892-9. PubMed ID: 16684830
[TBL] [Abstract][Full Text] [Related]
35. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
36. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
[TBL] [Abstract][Full Text] [Related]
37. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma.
Taylor T; Specker B; Robbins J; Sperling M; Ho M; Ain K; Bigos ST; Brierley J; Cooper D; Haugen B; Hay I; Hertzberg V; Klein I; Klein H; Ladenson P; Nishiyama R; Ross D; Sherman S; Maxon HR
Ann Intern Med; 1998 Oct; 129(8):622-7. PubMed ID: 9786809
[TBL] [Abstract][Full Text] [Related]
38. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?
Hindié E; Mellière D; Lange F; Hallaj I; de Labriolle-Vaylet C; Jeanguillaume C; Lange J; Perlemuter L; Askienazy S
Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):974-81. PubMed ID: 12734689
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
40. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age.
Petrich T; Widjaja A; Musholt TJ; Hofmann M; Brunkhorst T; Ehrenheim C; Oetting G; Knapp WH
Eur J Nucl Med; 2001 Feb; 28(2):203-8. PubMed ID: 11303891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
